DECLARE-TIMI 58: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

• For newly diagnosed T2DM with A1C <7.5%, SGLT-2 inhibitors are suitable alternatives to metformin in select patients. i.e heart failure established CVD or CKD.

• All SGLT-2 inhibitors should be stopped 24 hours prior to surgery

• Increased risk for bone fractures from postmarketing surveillance data (same for canagliflozin)



Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357.

About the author 


The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates